Krystal Biotech (KRYS) reported Q4 net income Wednesday of $1.52 per diluted share, up from $0.30 a year earlier.

Analysts polled by FactSet expected $1.18.

Revenue for the quarter ended Dec. 31 was $91.1 million, compared with $42.1 million a year earlier.

Analysts surveyed by FactSet expected $90.6 million.

Shares of Krystal Biotech were down 4.3% in recent pre-market activity.